Wegovy vs. Saxenda
See how Wegovy and Saxenda compare on approved uses, dosing, side effects, and cost.
Key Takeaways
Wegovy is injected once a week while Saxenda requires a daily injection, a major convenience difference for many patients.
Wegovy is the only one of the two FDA-approved to reduce cardiovascular risk in adults with established heart disease and obesity or overweight.
Both drugs share the same boxed warning for thyroid C-cell tumors and cause similar GI side effects, though the exact rates differ slightly between them.
Wegovy vs. Saxenda Drug Summary
Wegovy
Wegovy (semaglutide) is a GLP-1 receptor agonist used for chronic weight management in adults and adolescents with obesity, and to reduce cardiovascular risk in adults with heart disease and obesity. It is injected once a week, with the dose gradually increased over about four months to a 2.4 mg maintenance level.
Saxenda
Saxenda (liraglutide) is a GLP-1 receptor agonist used for chronic weight management in adults and adolescents with obesity. It is injected once a day, with the dose increased weekly over about a month until it reaches the 3 mg maintenance level.
Wegovy vs. Saxenda Side Effects
Wegovy
Saxenda
Wegovy vs. Saxenda Dosage
Wegovy
Saxenda
| STAGE | DOSE | WHEN |
| Starting dose | 0.25 mg once weekly | Weeks 1-4 |
| Maximum dose | 2.4 mg once weekly | Week 17 onward |
| Dose changes | 4 increases | Every 4 weeks |
| STAGE | DOSE | WHEN |
| Starting dose | 0.6 mg once daily | Week 1 |
| Maximum dose | 3 mg once daily | Week 5 onward |
| Dose changes | 4 increases | Every week |
Wegovy
| STAGE | DOSE | WHEN |
| Starting dose | 0.25 mg once weekly | Weeks 1-4 |
| Maximum dose | 2.4 mg once weekly | Week 17 onward |
| Dose changes | 4 increases | Every 4 weeks |
Saxenda
| STAGE | DOSE | WHEN |
| Starting dose | 0.6 mg once daily | Week 1 |
| Maximum dose | 3 mg once daily | Week 5 onward |
| Dose changes | 4 increases | Every week |
Wegovy vs. Saxenda Indications
Wegovy
Wegovy is FDA-approved for chronic weight management in adults and adolescents 12 and older who have obesity, or overweight with a weight-related condition, alongside diet and exercise. It is also approved to lower the risk of major cardiovascular events in adults with established heart disease who have obesity or overweight.
Weight management in adults with obesity or overweight plus a weight-related condition
Weight management in adolescents 12 and older with obesity
Reduce cardiovascular risk in adults with obesity or overweight and heart disease
Saxenda
Saxenda is FDA-approved for chronic weight management in adults who have obesity, or overweight with a weight-related condition, alongside diet and exercise. It is also approved for adolescents ages 12 to 17 with obesity.
Weight management in adults with obesity or overweight plus a weight-related condition
Weight management in adolescents 12 to 17 with obesity
Used together with diet and exercise
Wegovy vs. Saxenda Pros and Cons
Wegovy
Wegovy's once-weekly schedule and its added cardiovascular indication set it apart from Saxenda, though the two drugs share the same class-wide warnings. Insurance coverage for either drug varies widely and often depends on the specific diagnosis code used for approval.
Pros
Only needs one injection per week instead of daily
FDA-approved to reduce risk of heart attack, stroke, and cardiovascular death in adults with heart disease
Uses a higher maintenance dose (2.4 mg) that may support greater weight loss
Cons
Newer drug with less long-term real-world experience than Saxenda
Reported rates of nausea and vomiting are somewhat higher than Saxenda's
Same thyroid tumor boxed warning, so the same contraindications apply
Saxenda
Saxenda has a longer track record since its 2014 approval, but its daily injection requirement is a meaningful trade-off against Wegovy's weekly dosing. Both drugs carry the same thyroid tumor boxed warning and depend on insurance formularies for affordability.
Pros
Approved since 2014, giving it a longer track record in clinical use
Slightly lower reported rates of nausea and vomiting in trials
Daily dosing allows finer day-to-day adjustment of injection timing
Cons
Requires a daily injection instead of once a week
Label carries added warnings for increased heart rate and suicidal thoughts monitoring
Not approved for cardiovascular risk reduction like Wegovy
Common Symptoms and Related Diseases You Can Explore
Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.